Zanidatamab
Jazz and Zymeworks’ Ziihera Achieves Practice-Changing Results in Phase 3 Trial for First-Line HER2-Positive Gastroesophageal Adenocarcinoma
Ziihera; zanidatamab; Jazz Pharmaceuticals; Zymeworks; HER2; gastroesophageal adenocarcinoma; HERIZON-GEA-01; stomach cancer
Jazz and Zymeworks Bispecific Antibody Zanidatamab Delivers Practice-Changing Results in Stomach Cancer Study
Jazz Pharmaceuticals; Zymeworks; zanidatamab; bispecific antibody; HER2; gastroesophageal adenocarcinoma; stomach cancer; phase 2 trial; phase 3 HERIZON-GEA-01; overall survival; progression-free survival; chemotherapy; practice-changing; Orphan Drug designation
Zanidatamab Demonstrates Promising 30-Month Survival Rate in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
Zanidatamab, HER2-positive, metastatic gastroesophageal adenocarcinoma, bispecific antibody, survival rate, gastric cancer, oncology.
Jazz Pharmaceuticals Presents Groundbreaking HER2 Biliary Tract Cancer Data Ahead of FDA Decision
Jazz Pharmaceuticals, HER2, Biliary Tract Cancer, FDA Decision, Zanidatamab, Priority Review